Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 28;16(1):85.
doi: 10.1186/s13045-023-01475-9.

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Jiazheng Yu #  1 , Siyu Wu #  1 , Rong Li #  1 , Yuanhong Jiang  1 , Jianyi Zheng  1 , Zeyu Li  1 , Mingyang Li  1 , Kerong Xin  1 , Xiaojiao Guan  2 , Shijie Li  3 , Xiaonan Chen  4
Affiliations

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Jiazheng Yu et al. J Hematol Oncol. .

Abstract

Antibody-drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.

Keywords: ADCs; Disitamab vedotin; Enfortumab vedotin; Sacituzumab govitecan; Urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. O'Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, McKay RR, et al. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. J Clin Oncol. 2023;41(6_suppl):499. doi: 10.1200/JCO.2023.41.6_suppl.499. - DOI
    1. Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, et al. Study EV-104: phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—trial in progress. J Clin Oncol. 2023;41(6_sippl):TPS582. doi: 10.1200/JCO.2023.41.6_suppl.TPS582. - DOI
    1. Tagawa ST, Balar AV, Petrylak DP, Rezazadeh A, Loriot Y, Flechon A, et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI) J Clin Oncol. 2023;41(6_suppl):526. doi: 10.1200/JCO.2023.41.6_suppl.526. - DOI
    1. Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. J Clin Oncol. 2023;41(6_suppl):520. doi: 10.1200/JCO.2023.41.6_suppl.520. - DOI
    1. Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. J Clin Oncol. 2023;41(6_suppl):518. doi: 10.1200/JCO.2023.41.6_suppl.518. - DOI - PMC - PubMed

MeSH terms